Founded in 2004, DIURNAL®, a NEUROCRINE BIOSCIENCES® Company, is a European, UK-headquartered specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency.
Our expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body's natural hormone levels) to develop products for rare and chronic endocrine conditions
This section is a resource providing information on Diurnal medicines available in the EU. It is not intended to replace the advice of a qualified doctor.
Diurnal is a rapidly growing global specialty pharmaceutical company with a highly integrated and very committed team. We're always looking for talented individuals who share our vision. Visit this section to view our current opportunities.
Diurnal is committed to transparency in its interactions. Diurnal commits to following relevant pharmaceutical codes and has published details of its transfers of value below. Where individual countries have other transparency regulations, Diurnal's declarations for these can be found in the Transparency dropdown menu on a country-specific basis.
Diurnal is committed to transparency in clinical trials and publishes the protocols and results of its clinical trials on the website www.clinicaltrials.gov